Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 22, 2022
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rudnicka, M. (2022). Komentarz. Medycyna Faktów , 15(4(57), 397-398. https://doi.org/10.24292/01.MF.0422.3
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Tseng C-H. Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients. Front Endocrinol. 2021; 12: 637392. http://doi.org/10.3389/fendo.2021.637392.
2. Jackiewicz A, Katarzyńska J. Dipeptydylopeptydaza IV – atrakcyjny cel do opracowywania skutecznych strategii terapeutycznych i diagnostycznych. Postepy Hig Med Dosw (online). 2018; 72: 417-41.
3. Wiciński M, Górski K, Wódkiewicz E et al. Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. Int J Mol Sci. 2020; 21(7): 2275. http://doi.org/10.3390/ijms21072275.
4. Aghahoseini F, Alihemmati A, Hosseini L et al. Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress. J Diabetes Metab Disord. 2020; 19(2): 701-7. http://doi.org/10.1007/s40200-020-00548-7.
5. Li X, Meng C, Han F et al. Vildagliptin Attenuates Myocardial Dysfunction and Restores Autophagy via miR-21/SPRY1/ERK in Diabetic Mice Heart. Front Pharmacol. 2021; 12: 634365. http://doi.org/10.3389/fphar.2021.634365.
6. Liu Y, Qi Y. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix. Int Immunopharmacol. 2020; 87: 106774. http://doi.org/10.1016/j.intimp.2020.106774.
7. Wang Z, Xu M, Bai J et al. Vildagliptin reduced extracellular matrix degradation in human primary chondrocytes. Eur J Pharmacol. 2019; 844: 49-55.
8. Sherif IO, Alshaalan AA, Al-Shaalan NH. Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. Ren Fail. 2020; 42(1): 208-15. http://doi.org/10.1080/0886022X.2020.172918.
2. Jackiewicz A, Katarzyńska J. Dipeptydylopeptydaza IV – atrakcyjny cel do opracowywania skutecznych strategii terapeutycznych i diagnostycznych. Postepy Hig Med Dosw (online). 2018; 72: 417-41.
3. Wiciński M, Górski K, Wódkiewicz E et al. Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. Int J Mol Sci. 2020; 21(7): 2275. http://doi.org/10.3390/ijms21072275.
4. Aghahoseini F, Alihemmati A, Hosseini L et al. Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress. J Diabetes Metab Disord. 2020; 19(2): 701-7. http://doi.org/10.1007/s40200-020-00548-7.
5. Li X, Meng C, Han F et al. Vildagliptin Attenuates Myocardial Dysfunction and Restores Autophagy via miR-21/SPRY1/ERK in Diabetic Mice Heart. Front Pharmacol. 2021; 12: 634365. http://doi.org/10.3389/fphar.2021.634365.
6. Liu Y, Qi Y. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix. Int Immunopharmacol. 2020; 87: 106774. http://doi.org/10.1016/j.intimp.2020.106774.
7. Wang Z, Xu M, Bai J et al. Vildagliptin reduced extracellular matrix degradation in human primary chondrocytes. Eur J Pharmacol. 2019; 844: 49-55.
8. Sherif IO, Alshaalan AA, Al-Shaalan NH. Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. Ren Fail. 2020; 42(1): 208-15. http://doi.org/10.1080/0886022X.2020.172918.